Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/ efavirenz: 12-Week results from a randomized trial

AIDS

Volumn 19, Issue 11, 2005, Pages 1183-1188

  Maitland, Desmond ^a   Moyle, Graeme ^a   Hand, James ^a   Mandalia, Sundhiya ^a   Boffito, Marta ^a   Nelson, Mark ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral regimens; Didanosine; Naive HIV patients; Once daily therapy; Tenofovir

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT FAILURE; VIRUS LOAD; VIRUS RESISTANCE;

EID: 23044486337     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000176218.40861.14     Document Type: Article

References (23)

1. Carmona A, Knobel H, Guelar A, Grau S, Mateu-de Antonio J, Lopez-Colomes JL, et al. Factors influencing survival in HIV infected patients treated with HAART. Presented at: XIIIth International AIDS Conference. Durban, July 2000 [abstract TuOrB417].
2. Moyle G. The assessing patient's preferred treatments (APPT-1) study. Int J STD AIDS 2003; 14 (Suppl 1):34-36.
3. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral naive HIV-1 infected adults. AIDS 2001; 15:1369-1377.
4. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CCJ, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004; 292:251-265.
5. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, et al. Early virologic failure and with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005; 10:171-177.
6. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Topics in HIV Med 2004; 12:119-124.
7. Back D, Blaschke T, Boucher C, Burger D, Fletcher C, Flexner C, et al. Optimizing TDM in HIV clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Version 1.0. 2003. Available at: http:// www.hivpharmacology.com/.
8. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003; 17:2045-2052.
9. Gallant JE, Rodriguez AZ, Weinberg W, Young B, Berger D, Lim ML, et al. Early non-response to tenofovir (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 2003 [abstract H-1722a].
10. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-1 infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [Abstract 51].
11. Gulick RM, Ribaudo HJ, Shimuka CM, Lustgarten S, Meyer WA, Klingman K, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
12. Leon A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005; 19:213-215.
13. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
14. Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, et al. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003; 188:541-548.
15. Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase interactions between 2′3′-dideoxyinosine and allopurinol, ganciclovir or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-1095.
16. Kakuda T, Anderson P, Becker S. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/ nucleotide regimens may be related. AIDS 2004; 18:2442-2444.
17. Kearney B, Isaacson E, Sayre J. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. Presented at: 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 533].
18. Rendon A, Barrios A, Gonzalez de Requena D, Maida I, Labarga P, Martin-Carbonero L, et al. Didanosine plasma levels in patients taking tenofovir concomitantly: high interindividual variability but association with hyperlactatemia. HIV Med 2004; 5:233 [abstract 81].
19. Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacother 2003; 23:695-701.
20. Samarasinghe Y, Boffito M, Di Perri G. Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions. J HIV Ther 2004; 9:79-86.
21. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, et al. Unexpected CD4 cell-count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
22. Martinez E, Milinkovic A, De Lazzari E, Ravasi G, Blanco JL, Larrousse M, et al. Pancreatic toxic effects associated with co-adminstration of didansoine and tenofovir in HIV-infected adults. Lancet 2004; 364:8-10.
23. McColl DJ, Miller MD. The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. J Antimicrob Chemother 2003; 51:219-223.